| P/E (FY) | — | Sales (TTM) | $3.5M |
| Earnings (TTM) | -$86.3M | ROE | −145.07% |
| Net Margin | −2298.54% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $177.6M | Trading Days | 2433 |
| 52W High | 7.75 |
| 52W Low | 1.32 |
| % Off High | −55.87% |
| YTD | −44.21% | 1Y | 96.55% |
| 3Y | −84.63% | 5Y | −98.88% |
| 10Y | −99.05% | Since incept. (ann.) | −37.15% |
RD 100%
| Ann. Volatility (1Y) | 122.45% | Ann. Volatility (3Y) | 4328.26% |
| Sharpe (1Y) | 1.15 | Sharpe (3Y) | 0.59 |
| Max Drawdown (1Y) | −57.78% | Max Drawdown (3Y) | −99.36% |
| Beta (3Y, vs SPY) | 44.36 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| WHWK | Whitehawk Therapeutics, Inc. | $182.0M | — |
| PYXS | Pyxis Oncology, Inc. | $184.4M | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $170.7M | 2.8 |
| ANTX | AN2 Therapeutics, Inc. | $169.3M | — |
| IMRX | Immuneering Corp | $186.6M | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $168.3M | — |
| VERU | VERU INC. | $189.5M | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $164.7M | — |
| HELP | CYBIN INC. | $164.2M | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $163.4M | — |
| INDP | Indaptus Therapeutics, Inc. |
| $195.9M |
| — |
| KPTI | Karyopharm Therapeutics Inc. | $160.7M | — |
